Anti-PD-1 Induced Musculoskeletal Side Effects Successfully Treated With Hydroxychloroquine in Patients With Advanced Cutaneous Squamous Cell Carcinoma

array:23 ["pii" => "S0001731024005295" "issn" => "00017310" "doi" => "10.1016/j.ad.2023.10.050" "estado" => "S200" "fechaPublicacion" => "2024-10-02" "aid" => "4001" "copyright" => "AEDV" "copyrightAnyo" => "2024" "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "crp" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:17 [ "pii" => "S0001731024005933" "issn" => "00017310" "doi" => "10.1016/j.ad.2023.09.030" "estado" => "S200" "fechaPublicacion" => "2024-10-04" "aid" => "4022" "copyright" => "AEDV" "documento" => "article" "crossmark" => 0 "subdocumento" => "sco" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:9 [ "idiomaDefecto" => true "cabecera" => "FORO DE RESIDENTES" "titulo" => "FR - Isotretinoína como tratamiento de la dermatitis seborreica moderada-grave" "tienePdf" => "es" "tieneTextoCompleto" => "es" "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "RF - Safety and Efficacy of Isotretinoin for Moderate-to-Severe Seborrheic Dermatitis" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Luque-Luna, J. Gil-Lianes, R. Pigem" "autores" => array:3 [ 0 => array:2 [ "nombre" => "M." "apellidos" => "Luque-Luna" ] 1 => array:2 [ "nombre" => "J." "apellidos" => "Gil-Lianes" ] 2 => array:2 [ "nombre" => "R." "apellidos" => "Pigem" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024005933?idApp=UINPBA000044" "url" => "/00017310/unassign/S0001731024005933/v1_202410040438/es/main.assets" ] "itemAnterior" => array:17 [ "pii" => "S0001731023004908" "issn" => "00017310" "doi" => "10.1016/j.ad.2023.05.022" "estado" => "S200" "fechaPublicacion" => "2023-07-18" "aid" => "3547" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "crp" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Case and Research Letter" "titulo" => "Recalcitrant Hailey–Hailey Disease With Satisfactory Response to Apremilast" "tienePdf" => "en" "tieneTextoCompleto" => "en" "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Enfermedad de Hailey-Hailey recalcitrante con respuesta satisfactoria a apremilast" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2049 "Ancho" => 1555 "Tamanyo" => 362161 ] ] "descripcion" => array:1 [ "en" => "Red-brown plaques with superficial erosions and a macerated appearance, located in the axillary folds (A) and groin (B) before the start of treatment with apremilast. Note the improvement of the lesions after 6 months of treatment with apremilast 30mg twice a day (C and D)." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Mansilla-Polo, C. Abril-Pérez, M.Á. Navarro-Mira, R. Botella-Estrada" "autores" => array:4 [ 0 => array:2 [ "nombre" => "M." "apellidos" => "Mansilla-Polo" ] 1 => array:2 [ "nombre" => "C." "apellidos" => "Abril-Pérez" ] 2 => array:2 [ "nombre" => "M.Á." "apellidos" => "Navarro-Mira" ] 3 => array:2 [ "nombre" => "R." "apellidos" => "Botella-Estrada" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023004908?idApp=UINPBA000044" "url" => "/00017310/unassign/S0001731023004908/v1_202307180913/en/main.assets" ] "asociados" => array:1 [ 0 => array:17 [ "pii" => "S0001731024008081" "issn" => "00017310" "doi" => "10.1016/j.ad.2024.10.034" "estado" => "S100" "fechaPublicacion" => "2024-10-25" "aid" => "4125" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "crp" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:9 [ "idiomaDefecto" => true "cabecera" => "Carta científico-clínica" "titulo" => " Tratamiento con hidroxicloroquina de efectos secundarios musculoesqueléticos inducidos por anti-PD-1 en pacientes con carcinoma cutáneo de células escamosas avanzado" "tienePdf" => "es" "tieneTextoCompleto" => "es" "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Anti-PD-1 Induced Musculoskeletal Side Effects Successfully Treated With Hydroxychloroquine in Patients With Advanced Cutaneous Squamous Cell Carcinoma" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "I. Villegas-Romero, J.F. Millán-Cayetano, D. Jiménez-Gallo, T. Fernández-Morano, I. Navarro-Navarro, M. Linares-Barrios" "autores" => array:6 [ 0 => array:2 [ "nombre" => "I." "apellidos" => "Villegas-Romero" ] 1 => array:2 [ "nombre" => "J.F." "apellidos" => "Millán-Cayetano" ] 2 => array:2 [ "nombre" => "D." "apellidos" => "Jiménez-Gallo" ] 3 => array:2 [ "nombre" => "T." "apellidos" => "Fernández-Morano" ] 4 => array:2 [ "nombre" => "I." "apellidos" => "Navarro-Navarro" ] 5 => array:2 [ "nombre" => "M." "apellidos" => "Linares-Barrios" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024008081?idApp=UINPBA000044" "url" => "/00017310/unassign/S0001731024008081/v1_202410250439/es/main.assets" ] ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "Case and Research Letter" "titulo" => "Anti-PD-1 Induced Musculoskeletal Side Effects Successfully Treated With Hydroxychloroquine in Patients With Advanced Cutaneous Squamous Cell Carcinoma" "tieneTextoCompleto" => true "saludo" => "To the Editor," "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "I. Villegas-Romero, J.F. Millán-Cayetano, D. Jiménez-Gallo, T. Fernández-Morano, I. Navarro-Navarro, M. Linares-Barrios" "autores" => array:6 [ 0 => array:2 [ "nombre" => "I." "apellidos" => "Villegas-Romero" ] 1 => array:4 [ "nombre" => "J.F." "apellidos" => "Millán-Cayetano" "email" => array:1 [ 0 => "jf.millancayetano@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 2 => array:2 [ "nombre" => "D." "apellidos" => "Jiménez-Gallo" ] 3 => array:2 [ "nombre" => "T." "apellidos" => "Fernández-Morano" ] 4 => array:2 [ "nombre" => "I." "apellidos" => "Navarro-Navarro" ] 5 => array:2 [ "nombre" => "M." "apellidos" => "Linares-Barrios" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Department of Dermatology, Hospital Universitario Puerta del Mar, Cádiz, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tratamiento con hidroxicloroquina de efectos secundarios musculoesqueléticos inducidos por anti-PD-1 en pacientes con carcinoma cutáneo de células escamosas avanzado" ] ] "textoCompleto" => "Immunotherapy has become an important therapy in the management of advanced skin cancer. Monotherapy with anti-programmed cell death protein 1 (anti-PD-1) is currently the first-line therapy for advanced cutaneous squamous cell carcinoma (cSCC) in patients ineligible for curative surgery and/or radiotherapy. Cemiplimab has shown an objective response rate of 47.5% with a response duration of more than 6 months in 57% of responding patients.<a class="elsevierStyleCrossRef" href="#bib0050">1</a> Immune checkpoint inhibitors (ICI) modify the tumor immune microenvironment leading not only to anti-tumor responses but also immune-related adverse effects (irAEs).<a class="elsevierStyleCrossRefs" href="#bib0055">2,3</a> Rheumatic irAEs have been reported in approximately 10% of patients on ICI and there are currently no established guidelines for their therapeutic management, except for recommendations that include avoiding doses >10mg/day of prednisone or equivalent.<a class="elsevierStyleCrossRefs" href="#bib0065">4,5</a>We present three cases of advanced cSCC ON anti-PD-1 that presented arthralgia and/or myalgia which were successfully treated with hydroxychloroquine.<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005">-Case #1: An 83-year-old woman with cSCC in the right cheek and unresectable lymph node metastasis refractory to radiation therapy received pembrolizumab 2mg/kg every 3 weeks. The patient achieved complete clinical and radiological response after 6 cycles and maintained this response after 17 cycles. However, on dose #3, she presented with grade 2 arthromyalgia. Lab test results revealed a C-reactive protein (CRP) level of 33.5U/L (0–5mg/L), an erythrocyte sedimentation rate (ESR) of 21mm/h (1–20mm/h), and creatin-kinase (CK) levels of 41U/L (29–168U/L). At the onset of symptoms, she was prescribed 10mg/day of prednisone and oral hydroxychloroquine 200mg/12h which led to complete symptom relief within 3 weeks (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). Then, a maintenance treatment of 5mg/day of prednisone and hydroxychloroquine 200mg/12h was employed.<elsevierMultimedia ident="tbl0005"></elsevierMultimedia></li><li class="elsevierStyleListItem" id="lsti0010">-Case #2: An 82-year-old man with recurrent cSCC affecting the right inner canthus, who was ineligible for surgery or radiotherapy on pembrolizumab 2mg/kg every 3 weeks. He presented clinical and radiological response on cycle #5, which was maintained after 11 cycles. However, on cycle #3, he developed grade 2 arthromyalgia. Lab test results showed a CFP level of 60.5mg/L (0–5mg/L), an ESR of 32mm/h (1–20mm/h) and CK levels within the normal range. Symptoms resolved with a 1-month initial regimen of prednisone 10mg/day and oral hydroxychloroquine 200mg/day (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>), after which the treatment was down-titrated to 5mg/day of prednisone and hydroxychloroquine 200mg/day as maintenance therapy.</li><li class="elsevierStyleListItem" id="lsti0015">-Case #3: An 80-year-old man with locally advanced recurrent cSCC on his right wrist, refractory to radiotherapy on a 2-year regimen of cemiplimab 350mg every 3 weeks achieved sustained complete clinical response after treatment discontinuation. On cycle, he presented with grade 2 arthralgia. Blood test results revealed CRP levels of 9.5mg/L (0–5mg/L), an ESR of 46mm/h (1–20mm/h) and normal CK levels. He was successfully treated with hydroxychloroquine 200mg twice-daily (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).</li></ul>In all three cases, the rheumatoid factor and citrullinated peptide antibody tests were negative.Through these three cases we aim to highlight the effectiveness of hydroxychloroquine in the management of musculoskeletal side effects or rheumatic irAEs. As far as we know, this is the first study ever conducted to show complete resolution using hydroxychloroquine.Hydroxychloroquine is used in the management of various rheumatological, immunological and infectious diseases. In addition to its well-known anti-inflammatory, immunomodulatory, anti-infective, anti-thrombotic and metabolic effects<a class="elsevierStyleCrossRef" href="#bib0075">6</a> it also exhibits potent antiproliferative and antimutagenic properties.<a class="elsevierStyleCrossRef" href="#bib0080">7</a> Furthermore, it is usually considered a safe treatment with few adverse effects. Retinopathy, although concerning, is rare when administered at doses <5mg/kg/day<a class="elsevierStyleCrossRef" href="#bib0080">7</a> and is potentially reversible.The actual prevalence of rheumatic irAEs is estimated to be around 10% but there are limited studies reporting prevalence of this disease, likely due to their relatively mild nature and sometimes lacking clinical suspicion.<a class="elsevierStyleCrossRefs" href="#bib0065">4,8</a> The most common rheumatic irAEs include arthralgia, myalgia, arthritis and polymyalgia rheumatic-like syndrome.<a class="elsevierStyleCrossRef" href="#bib0070">5</a> Some studies indicate that the prevalence of arthralgia ranges from 1% up to 43% vs 1% up to 7% of arthritis.<a class="elsevierStyleCrossRef" href="#bib0070">5</a> These side effects are more commonly associate with anti-PD-1 drugs or combined ICI.<a class="elsevierStyleCrossRef" href="#bib0090">9</a> The estimated prevalence of arthralgia with pembrolizumab is estimated at 9–12% but may run unnoticed. Arthralgia typically affects large joints symmetrically<a class="elsevierStyleCrossRef" href="#bib0090">9</a> and tends to occur around the third or sixth month after the beginning of immunotherapy. Serological markers such as rheumatoid factor, citrullinated peptide antibody or CK levels are generally not elevated.<a class="elsevierStyleCrossRef" href="#bib0090">9</a>Managing irAEs can often be achieved without discontinuing immunotherapy, but it requires maintaining the prednisone dosage <10mg/day (or equivalent) to avoid compromising its efficacy.<a class="elsevierStyleCrossRef" href="#bib0065">4</a> Some irAEs can persist despite treatment discontinuation. While the Cancer Immunotherapy Society recommends the use of disease-modifying antirheumatic drugs, hydroxychloroquine is not currently mentioned as a potential corticosteroid-sparing agent.<a class="elsevierStyleCrossRef" href="#bib0075">6</a>In conclusion, whether used as monotherapy or as an adjuvant therapy hydroxychloroquine appears to be a safe and effective option to address musculoskeletal symptoms without compromising the efficacy of immunotherapy. Further studies are needed to validate its role in managing these patients.Conflict of interestsThe authors state that they have no conflict of interests." "textoCompletoSecciones" => array:1 [ "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Conflict of interests" ] 1 => array:2 [ "identificador" => "xack778646" "titulo" => "Acknowledgments" ] 2 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "F: female; M: male; CR: complete response; IHQ: immunohistochemistry; CK: creatine kinase; HCQ: hydroxychloroquine." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patient \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Age \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Tumor \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Differentiation \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Immune infiltrate \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">IHQ – PDL1 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Treatment \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Response \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">iRAEs \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Weeks until iRAEs \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">CK level \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">iRAEs initial treatment \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">iRAEs maintenance treatment \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Improvement \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Case #1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">83 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">cSCC – metastatic lymph node \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Moderately differentiated \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Moderate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">30% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pembrolizumab 2mg/kg/3 weeks \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Arthralgia and myalgia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Normal \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HCQ 200mg/12hPrednisone 10mg/day 4 weeks \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HCQ 200mg/12hPrednisone 5mg/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Significant \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Case #2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">82 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Unresectable cSCC \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Moderately differentiated \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Moderate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">40% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pembrolizumab 2mg/kg/3 weeks \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Arthralgia and myalgia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Normal \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HCQ 200mg/dayPrednisone 10mg/day 3 weeks \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HCQ 200mg/dayPrednisone 5mg/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Significant \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Case #3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">80 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Unresectable cSCC \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Well differentiated \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Poor \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><1% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Cemiplimab 350mg/3 weeks \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Arthralgia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Normal \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HCQ 200mg/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HCQ 200mg/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Significant \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3675173.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Demographic features, cancer types, immunotherapy and rheumatic immune-related adverse events (irAEs)." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:9 [ 0 => array:3 [ "identificador" => "bib0050" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inmunoterapia en cáncer cutáneo no melanoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "P. Bassas Freixas" 1 => "G. Aparicio Español" 2 => "V. García-Patos Briones" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ad.2018.09.013" "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2019" "volumen" => "110" "paginaInicial" => "353" "paginaFinal" => "359" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30837075" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0055" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Targeting regulatory T cells in tumor immunotherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M.J. Smyth" 1 => "S.F. Ngiow" 2 => "M.W. Teng" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/icb.2014.33" "Revista" => array:6 [ "tituloSerie" => "Immunol Cell Biol" "fecha" => "2014" "volumen" => "92" "paginaInicial" => "473" "paginaFinal" => "474" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24777313" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0060" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnosis and management of immune related adverse events (irAEs) in cancer immunotherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Y.H. Liu" 1 => "X.Y. Zang" 2 => "J.C. Wang" 3 => "S.S. Huang" 4 => "J. Xu" 5 => "P. Zhang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.biopha.2019.109437" "Revista" => array:5 [ "tituloSerie" => "Biomed Pharmacother" "fecha" => "2019" "volumen" => "120" "paginaInicial" => "109437" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31590992" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0065" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Kostine" 1 => "A. Finckh" 2 => "C.O. Bingham" 3 => "K. Visser" 4 => "J. Leipe" 5 => "H. Shulze-Koops" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2020-217139" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2021" "volumen" => "80" "paginaInicial" => "36" "paginaFinal" => "48" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32327425" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0070" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Roberts" 1 => "M. Smylie" 2 => "J. Walker" 3 => "N.S. Basappa" 4 => "Q. Chu" 5 => "M. Kolinsky" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10067-019-04451-2" "Revista" => array:6 [ "tituloSerie" => "Clin Rheumatol" "fecha" => "2019" "volumen" => "38" "paginaInicial" => "1513" "paginaFinal" => "1519" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30701346" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0075" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "D. Plantone" 1 => "T. Koudriavtseva" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40261-018-0656-y" "Revista" => array:5 [ "tituloSerie" => "Clin Drug Investig" "fecha" => "2018" "volumen" => "38" "paginaInicial" => "653" "paginaFinal" => "671" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0080" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "N. Abdel-Wahab" 1 => "M.E. Suarez-Almazor" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/rheumatology/kez297" "Revista" => array:6 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2019" "volumen" => "58" "paginaInicial" => "vii40" "paginaFinal" => "vii48" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31816084" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0085" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Buder-Bakhaya" 1 => "K. Benesova" 2 => "C. Schulz" 3 => "H. Anwar" 4 => "A. Dimitrakopoulou-Strauss" 5 => "T.F. Weber" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00262-017-2069-9" "Revista" => array:6 [ "tituloSerie" => "Cancer Immunol Immunother" "fecha" => "2018" "volumen" => "67" "paginaInicial" => "175" "paginaFinal" => "182" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29018908" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0090" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Musculoskeletal and rheumatic diseases induced by immune checkpoint inhibitors: a review of the literature" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "D. Benfaremo" 1 => "L. Manfredi" 2 => "M.M. Luchetti" 3 => "A. Gabrielli" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2174/1574886313666180508122332" "Revista" => array:6 [ "tituloSerie" => "Curr Drug Saf" "fecha" => "2018" "volumen" => "13" "paginaInicial" => "150" "paginaFinal" => "164" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29745339" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack778646" "titulo" => "Acknowledgments" "texto" => "The lead author had full access to all the data in the study and takes full responsibility for the integrity of data and the accuracy of data analysis. The undersigned declared no conflicts of interest, financial activities or any other relationships or activities that readers could perceive to have influenced the study, or give the appearance of having influenced the content of the submitted work. This study received no funding whatsoever." "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/00017310/unassign/S0001731024005295/v1_202410020425/en/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/00017310/unassign/S0001731024005295/v1_202410020425/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024005295?idApp=UINPBA000044"]

Statistics

Case and Research Letter

Anti-PD-1 Induced Musculoskeletal Side Effects Successfully Treated With Hydroxychloroquine in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Tratamiento con hidroxicloroquina de efectos secundarios musculoesqueléticos inducidos por anti-PD-1 en pacientes con carcinoma cutáneo de células escamosas avanzado

I. Villegas-Romero, J.F. Millán-Cayetano

Corresponding author

jf.millancayetano@gmail.com

Corresponding author.

, D. Jiménez-Gallo, T. Fernández-Morano, I. Navarro-Navarro, M. Linares-Barrios

Department of Dermatology, Hospital Universitario Puerta del Mar, Cádiz, Spain

Read

1093

Times
was read the article

267

Total PDF

826

Total HTML

Share statistics

 array:23 [
  "pii" => "S0001731024005295"
  "issn" => "00017310"
  "doi" => "10.1016/j.ad.2023.10.050"
  "estado" => "S200"
  "fechaPublicacion" => "2024-10-02"
  "aid" => "4001"
  "copyright" => "AEDV"
  "copyrightAnyo" => "2024"
  "documento" => "simple-article"
  "crossmark" => 0
  "subdocumento" => "crp"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:17 [
    "pii" => "S0001731024005933"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.09.030"
    "estado" => "S200"
    "fechaPublicacion" => "2024-10-04"
    "aid" => "4022"
    "copyright" => "AEDV"
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "sco"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:9 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">FORO DE RESIDENTES</span>"
      "titulo" => "FR - Isotretino&#237;na como tratamiento de la dermatitis seborreica moderada-grave"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "RF - Safety and Efficacy of Isotretinoin for Moderate-to-Severe Seborrheic Dermatitis"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M&#46; Luque-Luna, J&#46; Gil-Lianes, R&#46; Pigem"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Luque-Luna"
            ]
            1 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "Gil-Lianes"
            ]
            2 => array:2 [
              "nombre" => "R&#46;"
              "apellidos" => "Pigem"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024005933?idApp=UINPBA000044"
    "url" => "/00017310/unassign/S0001731024005933/v1_202410040438/es/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "S0001731023004908"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.05.022"
    "estado" => "S200"
    "fechaPublicacion" => "2023-07-18"
    "aid" => "3547"
    "copyright" => "AEDV"
    "documento" => "simple-article"
    "crossmark" => 0
    "subdocumento" => "crp"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letter</span>"
      "titulo" => "Recalcitrant Hailey&#8211;Hailey Disease With Satisfactory Response to Apremilast"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Enfermedad de Hailey-Hailey recalcitrante con respuesta satisfactoria a apremilast"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 2049
              "Ancho" => 1555
              "Tamanyo" => 362161
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Red-brown plaques with superficial erosions and a macerated appearance&#44; located in the axillary folds &#40;A&#41; and groin &#40;B&#41; before the start of treatment with apremilast&#46; Note the improvement of the lesions after 6 months of treatment with apremilast 30<span class="elsevierStyleHsp" style=""></span>mg twice a day &#40;C and D&#41;&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M&#46; Mansilla-Polo, C&#46; Abril-P&#233;rez, M&#46;&#193;&#46; Navarro-Mira, R&#46; Botella-Estrada"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Mansilla-Polo"
            ]
            1 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Abril-P&#233;rez"
            ]
            2 => array:2 [
              "nombre" => "M&#46;&#193;&#46;"
              "apellidos" => "Navarro-Mira"
            ]
            3 => array:2 [
              "nombre" => "R&#46;"
              "apellidos" => "Botella-Estrada"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023004908?idApp=UINPBA000044"
    "url" => "/00017310/unassign/S0001731023004908/v1_202307180913/en/main.assets"
  ]
  "asociados" => array:1 [
    0 => array:17 [
      "pii" => "S0001731024008081"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2024.10.034"
      "estado" => "S100"
      "fechaPublicacion" => "2024-10-25"
      "aid" => "4125"
      "copyright" => "AEDV"
      "documento" => "simple-article"
      "crossmark" => 0
      "subdocumento" => "crp"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "es" => array:9 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Carta cient&#237;fico-cl&#237;nica</span>"
        "titulo" => " Tratamiento con hidroxicloroquina de efectos secundarios musculoesquel&#233;ticos inducidos por anti-PD-1 en pacientes con carcinoma cut&#225;neo de c&#233;lulas escamosas avanzado"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Anti-PD-1 Induced Musculoskeletal Side Effects Successfully Treated With Hydroxychloroquine in Patients With Advanced Cutaneous Squamous Cell Carcinoma"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "I&#46; Villegas-Romero, J&#46;F&#46; Mill&#225;n-Cayetano, D&#46; Jim&#233;nez-Gallo, T&#46; Fern&#225;ndez-Morano, I&#46; Navarro-Navarro, M&#46; Linares-Barrios"
            "autores" => array:6 [
              0 => array:2 [
                "nombre" => "I&#46;"
                "apellidos" => "Villegas-Romero"
              ]
              1 => array:2 [
                "nombre" => "J&#46;F&#46;"
                "apellidos" => "Mill&#225;n-Cayetano"
              ]
              2 => array:2 [
                "nombre" => "D&#46;"
                "apellidos" => "Jim&#233;nez-Gallo"
              ]
              3 => array:2 [
                "nombre" => "T&#46;"
                "apellidos" => "Fern&#225;ndez-Morano"
              ]
              4 => array:2 [
                "nombre" => "I&#46;"
                "apellidos" => "Navarro-Navarro"
              ]
              5 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "Linares-Barrios"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024008081?idApp=UINPBA000044"
      "url" => "/00017310/unassign/S0001731024008081/v1_202410250439/es/main.assets"
    ]
  ]
  "en" => array:14 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letter</span>"
    "titulo" => "Anti-PD-1 Induced Musculoskeletal Side Effects Successfully Treated With Hydroxychloroquine in Patients With Advanced Cutaneous Squamous Cell Carcinoma"
    "tieneTextoCompleto" => true
    "saludo" => "<span class="elsevierStyleItalic">To the Editor</span>&#44;"
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "I&#46; Villegas-Romero, J&#46;F&#46; Mill&#225;n-Cayetano, D&#46; Jim&#233;nez-Gallo, T&#46; Fern&#225;ndez-Morano, I&#46; Navarro-Navarro, M&#46; Linares-Barrios"
        "autores" => array:6 [
          0 => array:2 [
            "nombre" => "I&#46;"
            "apellidos" => "Villegas-Romero"
          ]
          1 => array:4 [
            "nombre" => "J&#46;F&#46;"
            "apellidos" => "Mill&#225;n-Cayetano"
            "email" => array:1 [
              0 => "jf.millancayetano@gmail.com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          2 => array:2 [
            "nombre" => "D&#46;"
            "apellidos" => "Jim&#233;nez-Gallo"
          ]
          3 => array:2 [
            "nombre" => "T&#46;"
            "apellidos" => "Fern&#225;ndez-Morano"
          ]
          4 => array:2 [
            "nombre" => "I&#46;"
            "apellidos" => "Navarro-Navarro"
          ]
          5 => array:2 [
            "nombre" => "M&#46;"
            "apellidos" => "Linares-Barrios"
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Department of Dermatology&#44; Hospital Universitario Puerta del Mar&#44; C&#225;diz&#44; Spain"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Tratamiento con hidroxicloroquina de efectos secundarios musculoesquel&#233;ticos inducidos por anti-PD-1 en pacientes con carcinoma cut&#225;neo de c&#233;lulas escamosas avanzado"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Immunotherapy has become an important therapy in the management of advanced skin cancer&#46; Monotherapy with anti-programmed cell death protein 1 &#40;anti-PD-1&#41; is currently the first-line therapy for advanced cutaneous squamous cell carcinoma &#40;cSCC&#41; in patients ineligible for curative surgery and&#47;or radiotherapy&#46; Cemiplimab has shown an objective response rate of 47&#46;5&#37; with a response duration of more than 6 months in 57&#37; of responding patients&#46;<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">1</span></a> Immune checkpoint inhibitors &#40;ICI&#41; modify the tumor immune microenvironment leading not only to anti-tumor responses but also immune-related adverse effects &#40;irAEs&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">2&#44;3</span></a> Rheumatic irAEs have been reported in approximately 10&#37; of patients on ICI and there are currently no established guidelines for their therapeutic management&#44; except for recommendations that include avoiding doses &#62;10<span class="elsevierStyleHsp" style=""></span>mg&#47;day of prednisone or equivalent&#46;<a class="elsevierStyleCrossRefs" href="#bib0065"><span class="elsevierStyleSup">4&#44;5</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">We present three cases of advanced cSCC ON anti-PD-1 that presented arthralgia and&#47;or myalgia which were successfully treated with hydroxychloroquine&#46;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">-</span><p id="par0015" class="elsevierStylePara elsevierViewall">Case &#35;1&#58; An 83-year-old woman with cSCC in the right cheek and unresectable lymph node metastasis refractory to radiation therapy received pembrolizumab 2<span class="elsevierStyleHsp" style=""></span>mg&#47;kg every 3 weeks&#46; The patient achieved complete clinical and radiological response after 6 cycles and maintained this response after 17 cycles&#46; However&#44; on dose &#35;3&#44; she presented with grade 2 arthromyalgia&#46; Lab test results revealed a C-reactive protein &#40;CRP&#41; level of 33&#46;5<span class="elsevierStyleHsp" style=""></span>U&#47;L &#40;0&#8211;5<span class="elsevierStyleHsp" style=""></span>mg&#47;L&#41;&#44; an erythrocyte sedimentation rate &#40;ESR&#41; of 21<span class="elsevierStyleHsp" style=""></span>mm&#47;h &#40;1&#8211;20<span class="elsevierStyleHsp" style=""></span>mm&#47;h&#41;&#44; and creatin-kinase &#40;CK&#41; levels of 41<span class="elsevierStyleHsp" style=""></span>U&#47;L &#40;29&#8211;168<span class="elsevierStyleHsp" style=""></span>U&#47;L&#41;&#46; At the onset of symptoms&#44; she was prescribed 10<span class="elsevierStyleHsp" style=""></span>mg&#47;day of prednisone and oral hydroxychloroquine 200<span class="elsevierStyleHsp" style=""></span>mg&#47;12<span class="elsevierStyleHsp" style=""></span>h which led to complete symptom relief within 3 weeks &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46; Then&#44; a maintenance treatment of 5<span class="elsevierStyleHsp" style=""></span>mg&#47;day of prednisone and hydroxychloroquine 200<span class="elsevierStyleHsp" style=""></span>mg&#47;12<span class="elsevierStyleHsp" style=""></span>h was employed&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">-</span><p id="par0020" class="elsevierStylePara elsevierViewall">Case &#35;2&#58; An 82-year-old man with recurrent cSCC affecting the right inner canthus&#44; who was ineligible for surgery or radiotherapy on pembrolizumab 2<span class="elsevierStyleHsp" style=""></span>mg&#47;kg every 3 weeks&#46; He presented clinical and radiological response on cycle &#35;5&#44; which was maintained after 11 cycles&#46; However&#44; on cycle &#35;3&#44; he developed grade 2 arthromyalgia&#46; Lab test results showed a CFP level of 60&#46;5<span class="elsevierStyleHsp" style=""></span>mg&#47;L &#40;0&#8211;5<span class="elsevierStyleHsp" style=""></span>mg&#47;L&#41;&#44; an ESR of 32<span class="elsevierStyleHsp" style=""></span>mm&#47;h &#40;1&#8211;20<span class="elsevierStyleHsp" style=""></span>mm&#47;h&#41; and CK levels within the normal range&#46; Symptoms resolved with a 1-month initial regimen of prednisone 10<span class="elsevierStyleHsp" style=""></span>mg&#47;day and oral hydroxychloroquine 200<span class="elsevierStyleHsp" style=""></span>mg&#47;day &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#44; after which the treatment was down-titrated to 5<span class="elsevierStyleHsp" style=""></span>mg&#47;day of prednisone and hydroxychloroquine 200<span class="elsevierStyleHsp" style=""></span>mg&#47;day as maintenance therapy&#46;</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">-</span><p id="par0025" class="elsevierStylePara elsevierViewall">Case &#35;3&#58; An 80-year-old man with locally advanced recurrent cSCC on his right wrist&#44; refractory to radiotherapy on a 2-year regimen of cemiplimab 350<span class="elsevierStyleHsp" style=""></span>mg every 3 weeks achieved sustained complete clinical response after treatment discontinuation&#46; On cycle&#44; he presented with grade 2 arthralgia&#46; Blood test results revealed CRP levels of 9&#46;5<span class="elsevierStyleHsp" style=""></span>mg&#47;L &#40;0&#8211;5<span class="elsevierStyleHsp" style=""></span>mg&#47;L&#41;&#44; an ESR of 46<span class="elsevierStyleHsp" style=""></span>mm&#47;h &#40;1&#8211;20<span class="elsevierStyleHsp" style=""></span>mm&#47;h&#41; and normal CK levels&#46; He was successfully treated with hydroxychloroquine 200<span class="elsevierStyleHsp" style=""></span>mg twice-daily &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46;</p></li></ul></p><p id="par0030" class="elsevierStylePara elsevierViewall">In all three cases&#44; the rheumatoid factor and citrullinated peptide antibody tests were negative&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">Through these three cases we aim to highlight the effectiveness of hydroxychloroquine in the management of musculoskeletal side effects or rheumatic irAEs&#46; As far as we know&#44; this is the first study ever conducted to show complete resolution using hydroxychloroquine&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">Hydroxychloroquine is used in the management of various rheumatological&#44; immunological and infectious diseases&#46; In addition to its well-known anti-inflammatory&#44; immunomodulatory&#44; anti-infective&#44; anti-thrombotic and metabolic effects<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">6</span></a> it also exhibits potent antiproliferative and antimutagenic properties&#46;<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">7</span></a> Furthermore&#44; it is usually considered a safe treatment with few adverse effects&#46; Retinopathy&#44; although concerning&#44; is rare when administered at doses &#60;5<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;day<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">7</span></a> and is potentially reversible&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">The actual prevalence of rheumatic irAEs is estimated to be around 10&#37; but there are limited studies reporting prevalence of this disease&#44; likely due to their relatively mild nature and sometimes lacking clinical suspicion&#46;<a class="elsevierStyleCrossRefs" href="#bib0065"><span class="elsevierStyleSup">4&#44;8</span></a> The most common rheumatic irAEs include arthralgia&#44; myalgia&#44; arthritis and polymyalgia rheumatic-like syndrome&#46;<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">5</span></a> Some studies indicate that the prevalence of arthralgia ranges from 1&#37; up to 43&#37; vs 1&#37; up to 7&#37; of arthritis&#46;<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">5</span></a> These side effects are more commonly associate with anti-PD-1 drugs or combined ICI&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">9</span></a> The estimated prevalence of arthralgia with pembrolizumab is estimated at 9&#8211;12&#37; but may run unnoticed&#46; Arthralgia typically affects large joints symmetrically<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">9</span></a> and tends to occur around the third or sixth month after the beginning of immunotherapy&#46; Serological markers such as rheumatoid factor&#44; citrullinated peptide antibody or CK levels are generally not elevated&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">9</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">Managing irAEs can often be achieved without discontinuing immunotherapy&#44; but it requires maintaining the prednisone dosage &#60;10<span class="elsevierStyleHsp" style=""></span>mg&#47;day &#40;or equivalent&#41; to avoid compromising its efficacy&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">4</span></a> Some irAEs can persist despite treatment discontinuation&#46; While the Cancer Immunotherapy Society recommends the use of disease-modifying antirheumatic drugs&#44; hydroxychloroquine is not currently mentioned as a potential corticosteroid-sparing agent&#46;<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">6</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">In conclusion&#44; whether used as monotherapy or as an adjuvant therapy hydroxychloroquine appears to be a safe and effective option to address musculoskeletal symptoms without compromising the efficacy of immunotherapy&#46; Further studies are needed to validate its role in managing these patients&#46;</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflict of interests</span><p id="par0060" class="elsevierStylePara elsevierViewall">The authors state that they have no conflict of interests&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:3 [
        0 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Conflict of interests"
        ]
        1 => array:2 [
          "identificador" => "xack778646"
          "titulo" => "Acknowledgments"
        ]
        2 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "multimedia" => array:1 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">F&#58; female&#59; M&#58; male&#59; CR&#58; complete response&#59; IHQ&#58; immunohistochemistry&#59; CK&#58; creatine kinase&#59; HCQ&#58; hydroxychloroquine&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patient&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Age&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Tumor&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Differentiation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Immune infiltrate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">IHQ &#8211; PDL1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Treatment&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Response&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">iRAEs&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Weeks until iRAEs&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">CK level&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">iRAEs initial treatment&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">iRAEs maintenance treatment&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Improvement&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Case &#35;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">83&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">cSCC &#8211; metastatic lymph node&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Moderately differentiated&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">30&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pembrolizumab 2<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;3 weeks&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Arthralgia and myalgia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Normal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HCQ 200<span class="elsevierStyleHsp" style=""></span>mg&#47;12<span class="elsevierStyleHsp" style=""></span>hPrednisone 10<span class="elsevierStyleHsp" style=""></span>mg&#47;day 4 weeks&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HCQ 200<span class="elsevierStyleHsp" style=""></span>mg&#47;12<span class="elsevierStyleHsp" style=""></span>hPrednisone 5<span class="elsevierStyleHsp" style=""></span>mg&#47;day&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Significant&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Case &#35;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">82&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Unresectable cSCC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Moderately differentiated&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Moderate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pembrolizumab 2<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;3 weeks&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Arthralgia and myalgia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Normal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HCQ 200<span class="elsevierStyleHsp" style=""></span>mg&#47;dayPrednisone 10<span class="elsevierStyleHsp" style=""></span>mg&#47;day 3 weeks&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HCQ 200<span class="elsevierStyleHsp" style=""></span>mg&#47;dayPrednisone 5<span class="elsevierStyleHsp" style=""></span>mg&#47;day&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Significant&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Case &#35;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">80&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Unresectable cSCC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Well differentiated&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Poor&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;1&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cemiplimab 350<span class="elsevierStyleHsp" style=""></span>mg&#47;3 weeks&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Arthralgia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Normal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HCQ 200<span class="elsevierStyleHsp" style=""></span>mg&#47;day&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HCQ 200<span class="elsevierStyleHsp" style=""></span>mg&#47;day&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Significant&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3675173.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Demographic features&#44; cancer types&#44; immunotherapy and rheumatic immune-related adverse events &#40;irAEs&#41;&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:9 [
            0 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Inmunoterapia en c&#225;ncer cut&#225;neo no melanoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "P&#46; Bassas Freixas"
                            1 => "G&#46; Aparicio Espa&#241;ol"
                            2 => "V&#46; Garc&#237;a-Patos Briones"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2018.09.013"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2019"
                        "volumen" => "110"
                        "paginaInicial" => "353"
                        "paginaFinal" => "359"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30837075"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Targeting regulatory T cells in tumor immunotherapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "M&#46;J&#46; Smyth"
                            1 => "S&#46;F&#46; Ngiow"
                            2 => "M&#46;W&#46; Teng"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/icb.2014.33"
                      "Revista" => array:6 [
                        "tituloSerie" => "Immunol Cell Biol"
                        "fecha" => "2014"
                        "volumen" => "92"
                        "paginaInicial" => "473"
                        "paginaFinal" => "474"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24777313"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Diagnosis and management of immune related adverse events &#40;irAEs&#41; in cancer immunotherapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "Y&#46;H&#46; Liu"
                            1 => "X&#46;Y&#46; Zang"
                            2 => "J&#46;C&#46; Wang"
                            3 => "S&#46;S&#46; Huang"
                            4 => "J&#46; Xu"
                            5 => "P&#46; Zhang"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.biopha.2019.109437"
                      "Revista" => array:5 [
                        "tituloSerie" => "Biomed Pharmacother"
                        "fecha" => "2019"
                        "volumen" => "120"
                        "paginaInicial" => "109437"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31590992"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Kostine"
                            1 => "A&#46; Finckh"
                            2 => "C&#46;O&#46; Bingham"
                            3 => "K&#46; Visser"
                            4 => "J&#46; Leipe"
                            5 => "H&#46; Shulze-Koops"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2020-217139"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2021"
                        "volumen" => "80"
                        "paginaInicial" => "36"
                        "paginaFinal" => "48"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32327425"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Roberts"
                            1 => "M&#46; Smylie"
                            2 => "J&#46; Walker"
                            3 => "N&#46;S&#46; Basappa"
                            4 => "Q&#46; Chu"
                            5 => "M&#46; Kolinsky"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s10067-019-04451-2"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Rheumatol"
                        "fecha" => "2019"
                        "volumen" => "38"
                        "paginaInicial" => "1513"
                        "paginaFinal" => "1519"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30701346"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Current and future use of chloroquine and hydroxychloroquine in infectious&#44; immune&#44; neoplastic&#44; and neurological diseases&#58; a mini-review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "D&#46; Plantone"
                            1 => "T&#46; Koudriavtseva"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40261-018-0656-y"
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Drug Investig"
                        "fecha" => "2018"
                        "volumen" => "38"
                        "paginaInicial" => "653"
                        "paginaFinal" => "671"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "N&#46; Abdel-Wahab"
                            1 => "M&#46;E&#46; Suarez-Almazor"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/rheumatology/kez297"
                      "Revista" => array:6 [
                        "tituloSerie" => "Rheumatology &#40;Oxford&#41;"
                        "fecha" => "2019"
                        "volumen" => "58"
                        "paginaInicial" => "vii40"
                        "paginaFinal" => "vii48"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31816084"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46; Buder-Bakhaya"
                            1 => "K&#46; Benesova"
                            2 => "C&#46; Schulz"
                            3 => "H&#46; Anwar"
                            4 => "A&#46; Dimitrakopoulou-Strauss"
                            5 => "T&#46;F&#46; Weber"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00262-017-2069-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer Immunol Immunother"
                        "fecha" => "2018"
                        "volumen" => "67"
                        "paginaInicial" => "175"
                        "paginaFinal" => "182"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29018908"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Musculoskeletal and rheumatic diseases induced by immune checkpoint inhibitors&#58; a review of the literature"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "D&#46; Benfaremo"
                            1 => "L&#46; Manfredi"
                            2 => "M&#46;M&#46; Luchetti"
                            3 => "A&#46; Gabrielli"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2174/1574886313666180508122332"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Drug Saf"
                        "fecha" => "2018"
                        "volumen" => "13"
                        "paginaInicial" => "150"
                        "paginaFinal" => "164"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29745339"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
    "agradecimientos" => array:1 [
      0 => array:4 [
        "identificador" => "xack778646"
        "titulo" => "Acknowledgments"
        "texto" => "<p id="par0065" class="elsevierStylePara elsevierViewall">The lead author had full access to all the data in the study and takes full responsibility for the integrity of data and the accuracy of data analysis&#46; The undersigned declared no conflicts of interest&#44; financial activities or any other relationships or activities that readers could perceive to have influenced the study&#44; or give the appearance of having influenced the content of the submitted work&#46; This study received no funding whatsoever&#46;</p>"
        "vista" => "all"
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/00017310/unassign/S0001731024005295/v1_202410020425/en/main.assets"
  "Apartado" => null
  "PDF" => "https://static.elsevier.es/multimedia/00017310/unassign/S0001731024005295/v1_202410020425/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024005295?idApp=UINPBA000044"
]

Article information

ISSN: 00017310
Original language: English

DOI:10.1016/j.ad.2023.10.050

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	17	8	25
2024 October	266	77	343
2024 September	148	38	186
2024 August	191	68	259
2024 July	204	76	280

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter